KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Profit After Tax: 2012-2024

Historic Profit After Tax for Xenon Pharmaceuticals (XENE) over the last 13 years, with Dec 2024 value amounting to -$234.3 million.

  • Xenon Pharmaceuticals' Profit After Tax fell 44.76% to -$90.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$306.3 million, marking a year-over-year decrease of 43.56%. This contributed to the annual value of -$234.3 million for FY2024, which is 28.48% down from last year.
  • As of FY2024, Xenon Pharmaceuticals' Profit After Tax stood at -$234.3 million, which was down 28.48% from -$182.4 million recorded in FY2023.
  • In the past 5 years, Xenon Pharmaceuticals' Profit After Tax registered a high of -$28.8 million during FY2020, and its lowest value of -$234.3 million during FY2024.
  • In the last 3 years, Xenon Pharmaceuticals' Profit After Tax had a median value of -$182.4 million in 2023 and averaged -$180.7 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first spiked by 30.67% in 2020, then slumped by 173.54% in 2021.
  • Xenon Pharmaceuticals' Profit After Tax (Yearly) stood at -$28.8 million in 2020, then plummeted by 173.54% to -$78.9 million in 2021, then crashed by 58.94% to -$125.4 million in 2022, then tumbled by 45.48% to -$182.4 million in 2023, then declined by 28.48% to -$234.3 million in 2024.